Editorial Comment

Alireza Dehghanmanshadi¹, Charles C Peyton^{1

2}, Soroush Rais-Bahrami^{1

2

3

4}

Affiliations

¹ Department of Urology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
² O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
³ Department of Radiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
⁴ Reviewing Board, The Journal of Urology®.

Comment

Alireza Dehghanmanshadi et al. J Urol. 2025 Mar.

. 2025 Mar;213(3):321-322.

doi: 10.1097/JU.0000000000004346. Epub 2024 Dec 5.

Alireza Dehghanmanshadi¹, Charles C Peyton^{1

2}, Soroush Rais-Bahrami^{1

2

3

4}

¹ Department of Urology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
² O'Neal Comprehensive Cancer Center, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
³ Department of Radiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
⁴ Reviewing Board, The Journal of Urology®.

No abstract available

Comment on

Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel.
Pierorazio PM, Kleinmann N, Shabsigh A, Hu B, Raman JD, Kaimakliotis H, Sankin A, Singla N, Meads A, Burger B, Raju S, Louie MJ, Chamie K, Weizer A, Schoenberg M. Pierorazio PM, et al. J Urol. 2025 Mar;213(3):313-322. doi: 10.1097/JU.0000000000004331. Epub 2024 Nov 19. J Urol. 2025. PMID: 39561384 Clinical Trial.